1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Mitochondrial Metabolism

Mitochondrial Metabolism

Mitochondria use multiple carbon fuels to produce ATP and metabolites, including pyruvate, which is generated from glycolysis; amino acids such as glutamine; and fatty acids. These carbon fuels feed into the TCA cycle in the mitochondrial matrix to generate the reducing equivalents NADH and FADH2, which deliver their electrons to the electron transport chain. Mitochondria are complex organelles that play an important role in many facets of cellular function, from metabolism to immune regulation and cell death. Mitochondria are actively involved in a wide variety of cellular processes and molecular interactions, such as calcium buffering, lipid flux, and intracellular signaling. It is increasingly recognized that mitochondrial dysfunction is a hallmark of many diseases such as obesity/diabetes, cancer, cardiovascular and neurodegenerative diseases. Mitochondrial metabolism is a key determinant of tumor progression by impacting on functions such as epithelial-to-mesenchymal transition. Mitochondrial metabolism and derived oncometabolites shape the epigenetic landscape to alter aggressiveness features of cancer cells. Changes in mitochondrial metabolism are relevant for the survival of tumors in response to therapy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-134832
    Mito-LND
    Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells.
    Mito-LND
  • HY-112177
    Myxothiazol
    Inhibitor 99.53%
    Myxothiazol, an antifungal antibiotic, is a mitochondrial electron transport chain complex III (bc1 complex) inhibitor. Myxothiazol inhibits the growth of many yeasts and fungi at concentrations between 0.01 and 3 μg/ml.
    Myxothiazol
  • HY-135231
    NL-1
    Inhibitor 99.45%
    NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC50s of 47.35 μM and 56.26 μM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.
    NL-1
  • HY-142684
    Pyruvate Carboxylase-IN-1
    Inhibitor 99.43%
    Pyruvate Carboxylase-IN-1 (compound 37) is a potent pyruvate carboxylase inhibitor with antiproliferative activity. The IC50 values ​​of pyruvate carboxylase-IN-1 against PC in cell lysates and cells are 0.204 and 0.104 μM, respectively.
    Pyruvate Carboxylase-IN-1
  • HY-P0125B
    Elamipretide triacetate
    Inhibitor 99.76%
    Elamipretide triacetate (MTP-131 triacetate; RX-31 triacetate; SS-31 triacetate) is Elamipretide triacetate form of Elamipretide (HY-P0125). Elamipretide triacetate is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury.
    Elamipretide triacetate
  • HY-B0887
    Permethrin
    Inhibitor 99.84%
    Permethrin (NRDC-143) is an insecticide, acaricide and a high selectively inhibitor of the Mitochondrial complex I, found in sediment and water samples. Permethrin shows estrogenic in vivo and anti-estrogenic activity in vitro. Permethrin also acts as a neurotoxin affecting neuron membranes by prolonging Sodium channel activation. Permethrin decreases resistance to bacterial infections in medaka (Oryzias latipes).
    Permethrin
  • HY-N2522
    Carboxyatractyloside dipotassium
    Inhibitor 99.57%
    Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats.
    Carboxyatractyloside dipotassium
  • HY-W012499
    N-Acetyl-L-methionine
    Inhibitor 99.93%
    N-Acetyl-L-methionine is a dietary supplementation. N-Acetyl-L-methionine increases caspase-3 activity and inhibits mitochondrial activity. N-Acetyl-L-methionine promotes lactation and improves meat quality.
    N-Acetyl-L-methionine
  • HY-W250122
    Glutamic acid sodium salt
    Inhibitor 99.23%
    Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
    Glutamic acid sodium salt
  • HY-144439
    HTS07545
    99.94%
    HTS07545 is a potent sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC50 of 30 nM. HTS07545 reduces the decomposition rate of hydrogen sulfide (H2S). HTS07545 can be used in the research of heart failure and pancreatic ductal adenocarcinoma.
    HTS07545
  • HY-128895
    KL1333
    Modulator 99.94%
    KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures.
    KL1333
  • HY-130055
    HQNO
    Inhibitor 99.19%
    HQNO, secreted by P. aeruginosa, is a potent electron transport chain inhibitor with a Kd of 64 nM for complex III. HQNO is a potent inhibitor of mitochondrial NDH-2 in many species.
    HQNO
  • HY-142035
    N-Propargylglycine
    99.70%
    N-Propargylglycine is an orally active irreversible inhibitor of proline dehydrogenase (PRODH). N-Propargylglycine has antitumor activity and can be used in the study of neurodegenerative diseases.
    N-Propargylglycine
  • HY-114936
    Piericidin A
    ≥99.0%
    Piericidin A (AR-054) is a natural mitochondrial NADH-ubiquinone oxidoreductase (complex I) inhibitor. Piericidin A is a potent neurotoxin and inhibits mitochondrial respiration by disrupting the electron transport system through its action on NADH-ubiquinone reductase. Piericidin A is also a potential quorum-sensing inhibitor that suppresses the expression of the virulence genes of Erwinia carotovora subsp. atroseptica (Eca). Piericidin A is an ADC cytotoxin and has anti-bacterial, anticancer, insecticidal activity.
    Piericidin A
  • HY-B0263
    Thiabendazole
    Inhibitor 99.94%
    Thiabendazole is an orally available benzimidazole fungicide with repellent and anticancer activities. Thiabendazole can result in developmental malformations. Thiabendazole can be used for modeling.
    Thiabendazole
  • HY-108022
    Azemiglitazone
    Inhibitor
    Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury.
    Azemiglitazone
  • HY-135869
    Mito-apocynin (C11)
    Inhibitor 99.84%
    Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function.
    Mito-apocynin (C11)
  • HY-122912
    ALDH1A inhibitor 673A
    Inhibitor 99.15%
    ALDH1A inhibitor 673A is an ALDH1A inhibitor with IC50s of 246 nM (ALDH1A1), 230 nM (ALDH1A2), 348 nM (ALDH1A3), respectively. ALDH1A inhibitor 673A has little or no inhibitory effect on other ALDH family members. ALDH1A inhibitor 673A induces necroptotic ovarian cancer stem-like cells (CSCs) death. ALDH1A inhibitor 673A induces DNA double stand breaks in cancer cells. ALDH1A inhibitor 673A can be used for the study of ovarian cancer.
    ALDH1A inhibitor 673A
  • HY-16397
    Phenformin
    Inhibitor 99.72%
    Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis.
    Phenformin
  • HY-W194810
    MCU-i11
    98.42%
    MCU-i11 is a negative regulator of the mitochondrial calcium uniporter (MCU) complex. MCU-i11 can reduce mitochondrial Ca2+ uptake. MCU-i11 impairs muscle cell growth. MCU-i11 can be used to study breast cancer, cervical cancer and neurological diseases.
    MCU-i11
Cat. No. Product Name / Synonyms Application Reactivity